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•	 	2019	‑Novel	Coronavirus	(2019	‑nCoV)	IgG	/	IgM	
GICA	Rapid	Test	Kit:	the test	results	of	this	prod‑
uct	cannot	be	used	as	a basis	for	diagnosis.
•	 	Novel	Coronavirus	(SARS	‑CoV	‑2)	IgM	/	IgG	
Antibody	Assay	Kit:	hemolysis,	lipemia,	and	mi‑
crobiological	pollution	can	affect	the test	result,	
such	specimen	is	not	to	be	examined.	Patients	
with	impaired	immunity	after	immunosuppres‑
sion	therapy,	HIV	‑positive,	and	/	or	receiving	im‑
munosuppressive	treatment	after	transplant	or	
receiving	therapy	have	impaired	immunologi‑
cal	response	and	their	results	can	lead	to	an in‑
correct	diagnosis.	If	the infection	is	suspected,	
the test	should	be	repeated	after	7	to	14	days.	
Both	the first	and	the second	specimen	should	be	
examined	at the same	time	to	determine	wheth‑
er	seroconversion	occurred	in	the primary	infec‑
tion.	Each	laboratory	should	work	out	its	own	ap‑
praisal	for	their	test	tubes.
•	 	SARS	‑CoV	‑2	IgM	/	IgG	Antibody	Rapid	Test:	
color	intensity	on	the T	‑line	may	not	be	asso‑
ciated	with	 the  antibodies	 concentration	 in	
the specimen.
•	 	Cellex	qSARS	‑CoV	‑2	IgG	/	IgM	Cassette	Rapid	
Test:	the intensity	of	the test	band	does	not	cor‑
relate	with	the virus	titer	in	the specimen.	Vi‑
ruses	with	mutations	in	the epitope	recognized	
by	the antibody	utilized	in	the test	could	provide	
a negative	result.	If	symptoms	persist,	along	with	
negative	results,	it	is	recommended	to	resample	
the patient	after	a few	days	or	test	them	with	
an alternative	testing	device.
•	 	The NADAL	COVID	‑19	IgG	/	IgM	Test:	the con‑
tinued	either	presence	or	absence	of	antibod‑
ies	may	not	be	used	to	determine	the success	or	
failure	of	therapy.	The results	of	immunosup‑
pressed	patients	should	be	interpreted	with	cau‑
tion.	A positive	test	result	can	also	appear	in	case	
of	negative	polymerase	chain	reaction	results,	be‑
cause	antibodies	are	still	present	in	the blood	af‑
ter	the disease	and,	hence,	can	be	detected.
•	 	Wuhan	Coronavirus	Rapid	Test	(2019	‑nCoV,	
COVID	‑19)	IgG	/	IgM:	frozen	and	thawed	samples	
(particularly	repeatedly)	contain	particles	that	
can	block	the membrane,	slow	down	the flow	of	
To the editor	 In	reference	to	a recent	publica‑
tion	by	Flisiak	et	al,1	we	would	like	to	draw	at‑
tention	to	the quickly	evolving	approach	to	rap‑
id	point	‑of	‑care	antibody	cassette	tests	for	se‑
vere	acute	respiratory	syndrome	coronavirus	2	
(SARS	‑CoV	‑2).	Numerous	manufacturers	offer	
rapid	point‑of‑care	cassette	tests,	which	detect	
immunoglobulin	M	(IgM)	and	immunoglobulin G	
(IgG)	antibodies	to	SARS	‑CoV	‑2	(TABLE 1).
Some	manufacturers	tested	the cross	‑reactivity	
of	their	products	with	antibodies	against	different	
pathogens,	but	none	of	them	tested	antibodies	
against	other	coronaviruses.	In	almost	all	cases,	
corresponding	manuals	warn	that	a negative	result	
does	not	exclude	SARS	‑CoV	‑2	infection.	They	also	
recommend	that	results	should	not	be	considered	
as	the sole	criteria	for	the diagnosis	of	COVID	‑19	
and	must	be	interpreted	together	with	other	clin‑
ical	data	(and	sometimes	epidemiological	and	/	or	
other	laboratory	results)	available	to	the physician.	
Some	manufactures	reported	additional	limitations	
and	requirements,	as	listed	below:
•	 	ACCU	‑TELL	COVID	‑19	IgG	/	IgM	Cassette:	
the continued	presence	or	absence	of	antibodies	
may	not	be	any	criterion	for	either	success	or	fail‑
ure	of	therapy.	Results	from	immunosuppressed	
patients	should	be	interpreted	carefully.
•	 	2019	‑nCoV	IgG	/	IgM	Rapid	Test	Cassette:	
the hematocrit	level	needs	to	be	between	25%	
and	65%	to	obtain	accurate	results.
•	 	Rapid	test	2019	‑nCOV	whole	blood:	the hema‑
tocrit	level	between	35%	and	65%	is	recommend‑
ed	for	the most	accurate	results.
•	 	The StrongStep	COVID	‑19	IgG	/	IgM	Combo	Test:	
clinical	diagnosis	should	not	be	based	on	the result	
of	a single	test,	but	should	be	established	after	con‑
sidering	all	the clinical	findings,	particularly	includ‑
ing	the reverse	transcriptase–polymerase	chain	re‑
action	test	for	SARS	‑CoV	‑2.
•	 	STANDARD	Q	COVID	‑19	IgM	/	IgG	Duo:	for	
more	accuracy	of	patients’	immune	status,	addi‑
tional	follow	‑up	testing	using	other	laboratory	
methods	is	recommended.
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460 TABLE 1 Comparison of selected rapid antibody cassette tests for severe acute respiratory syndrome coronavirus 2 (continued on the next page)
Test Manufacturer Sensitivity Specificity Total accuracy Recommended 
sample type
Sample size Time
ACCU ‑TELL COVID ‑19 IgG / IgM Cassette AccuBioTech Co., 
Ltd., China
IgG: 97.4%; 
IgM: 86.8%
IgG: 99.3%; IgM: 98.6% IgG: 98.9%; IgM: 96.1% serum, plasma, 
whole blood
10 μl 10 min
2019 ‑nCoV IgG / IgM Rapid Test Cassette 
(Whole Blood / Serum / Plasma)
Hangzhou AllTest 
Biotech Co., Ltd., 
China
IgG: 100%; 
IgM: 85%
IgG: 98%; IgM: 96% IgG: 98.6%; IgM: 92.9% serum, plasma, 
whole blood
10 μl of serum or 
plasma; 20 μl of 
fingertip blood or 
whole blood
10 min
Rapid test 2019 ‑nCOV blood myLAB, Poland – – – whole blood 20 μl 10 min
The StrongStep COVID ‑19 IgG / IgM Combo Test Liming Bio ‑Products 
Co., Ltd., China
IgG: 93.1%; 
IgM: 64.7%
IgG: 100%; IgM: 100% – serum, plasma, 
whole blood
10 μl 15 min
Novel Coronavirus (2019 ‑nCoV) Antibody 
IgG / IgM Assay (Colloidal Gold)
Avioq Biotechnology 
Co., Ltd., China
– – – serum, plasma, 
whole blood
10 μl 15 min
2019 ‑nCoV IgG & IgM Antibody Determination Kit Beijing Diagreat 
Biotechnologies Co., 
Ltd., China
– – – serum, plasma, 
whole blood
– 15 min
COVID ‑19 IgM / IgG Rapid Test BioMedomics, Inc., 
United States
88.66% 90.63% – serum, plasma, 
fingertip blood, 
whole blood
– 15 min
OnSite COVID ‑19 IgG / IgM Rapid Test CTK Biotech, Inc., 
United States
96.9% 99.4% – – – 10 min
STANDARD Q COVID ‑19 IgM / IgG Duo SD BIOSENSOR, Inc., 
Korea
81.8% 96.6% – serum, plasma, 
whole blood
10 μl 10–15 min
2019 ‑Novel Coronavirus (2019 ‑nCoV) IgG / IgM 
GICA Rapid Test Kit
Shenzhen Bioeasy 
Biotechnology Co., 
Ltd., China
89.56% 
(plasma: 
90.3%; 
serum: 
89.47%; 
whole blood: 
88.89%)
99.8% (plasma: 100%; serum: 
99.39%; whole blood: 100%)
94.68% serum, plasma, 
whole blood
10 μl 10–15 min
VivaDiagTM COVID ‑19 IgM / IgG Rapid Test VivaChek 
Laboratories, Inc., 
United States
100% Infection time, 4–10 days; IgM and 
IgG: 81.25%
Infection time, 11–24 days; IgM 
and IgG: 97.1%
Infection time, 4–10 days; IgM and 
IgG: 94.6%
Infection time, 11–24 days; IgM and 
IgG: 99.3% and 95.1%, respectively
whole blood 10 μl 15 min
SARS ‑CoV ‑2 IgG / IgM Rapid Qualitative Test Kit Xiamen Biotime 
Biotechnology Co., 
Ltd., China
– – – – 10 μl 10–15 min
One Step Test for Novel Coronavirus 
(2019 ‑nCoV) IgM / IgG Antibody
Getein Biotech, Inc., 
China
94.1% 95.1% – serum, plasma, 
fingertip blood, 
whole blood
10 μl of serum or 
plasma; 20 μl of 
fingertip blood or 
whole blood
10–20 min
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reagents,	and	may	lead	to	a high	background	col‑
or,	making	the interpretation	of	results	difficult.	
Specimens	containing	the unusually	high	titer	of	
heterophile	antibodies	or	rheumatoid	factor	also	
may	affect	results.
Rapid	antibody	tests	are	simple	in	use,	fast,	and	
cheap,	but	they	have	several	limitations.	First	of	
all,	they	are	useless	for	the detection	of	infection	
in	early	and	even	mid	phases.	The number	of	an‑
tibodies	produced	in	response	to	SARS	‑CoV	‑2	in‑
fection	increases	relatively	late,	several	days	after	
the onset	of	symptoms.2-4	This	disqualifies	such	
tests	from	„on	admission”	diagnostic	workup	due	
to	a huge	number	of	false	‑negative	results.	This	
observation	was	reported	in	Poland,	Czech	Repub‑
lic,	Spain,	and	Italy.5	None	of	the analyzed	kits	
was	tested	for	potential	cross	‑reactivity	with	an‑
tibodies	against	other	Betacoronaviruses	(HKU1,	
NL63,	OC43,	or	229E),	which	could	be	potential‑
ly	responsible	for	false	‑positive	results.	The initial	
World	Health	Organization	protocols	and	the Wu‑
han	handbook,	followed	by	regional	experts,	did	
not	recommend	the use	of	rapid	antibody	tests	in	
the diagnostic	procedures	related	to	COVID	‑19.6	
The reference	methods	for	diagnosing	patients	in‑
fected	with	SARS	‑CoV	‑2	involve	the molecular	ap‑
proach.	Currently,	enormous	progress	in	this	field	
is	being	observed.	The Food	and	Drug	Administra‑
tion	approved	the use	of	a few	point‑of‑care	mo‑
lecular	analyzers	and	tests	worldwide	or	limited	
to	the United	States	territory.7	Also	in	China	and	
Europe,	similar	technology	has	been	developed.	
Bosch	Healthcare	Solutions	presented	the rapid	
molecular	diagnostic	test	on	the Vivalytic	anal‑
ysis	device.8	However,	the shortage	of	molecu‑
lar	tests,	their	relatively	high	prices,	particularly	
as	compared	with	antibody	measurements,	and	
the increasing	number	of	convalescents,	includ‑
ing	persons	after	an oligosymptomatic	and	even	
asymptomatic	course	of	the disease,	may	change	
this	situation.	In	particular,	the percentage	of	as‑
ymptomatic	cases	is	not	clear	and	ranges	from	
10%	to	80%	of	the entire	infected	population.9,10	
The molecular	testing	of	a person	belonging	to	
this	crescent	group	of	convalescents	is	useless	due	
to	the absence	of	the virus.	Therefore,	the need	
for	antibody	testing	was	developed	by	the World	
Health	Organization	in	the interim	guidelines	as	
of	March	19,	2020.11	This	necessity	was	also	not‑
ed	by	the Food	and	Drug	Administration	and	oth‑
er	national	associations,	which	approved	5	rapid	
antibody	test	kits	for	detecting	SARS	‑CoV	‑2	on	
March	30,	2020.1,12	These	tests	can	be	used	sole‑
ly	by	medical	professionals,	because	only	this	
group	can	ensure	that	the samples	are	processed	
properly	and	the results	are	interpreted	correct‑
ly.	Additionally,	the European	Commission	and	
the	European	Union	member	states	are	funding	
fast	‑track	clinical	validation	studies	on	rapid	diag‑
nostic	tests	for	SARS	‑CoV	‑2,	conducted	by	hospi‑
tal	laboratories	in	several	European	Union	mem‑
ber	states.	It	is	expected	that	the utility	and	re‑
liability	of	the subsequent	tests	will	be	soon	de‑
fined.13	It	should	be	clearly	stated	that,	according	TA
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to	current	global	recommendations,	molecular	
testing	is	the only	way	to	diagnose	the presence	of	
SARS	‑CoV	‑2	infection.	However,	in	our	opinion,	
antibody	cassette	tests	for	SARS	‑CoV	‑2	should	be	
considered	in	the following	situations:	1)	to	cohort	
immunocompetent	and	nonimmunocompetent	
persons.	The cost	‑effectiveness	of	such	testing	
is	still	limited	due	to	the yet	relatively	low	num‑
ber	of	convalescents,	but	within	several	weeks	or	
months,	with	an increasing	number	of	ill	and	con‑
valescent	persons,	rapid	antibody	testing	would	
be	an easy	diagnostic	tool	of	low	cost.	First	of	all,	
it	should	be	recommended	for	medical	staff,	sol‑
diers,	and	persons	working	close	to	each	other,	
as	well	as	be	used	to	optimize	qualification	for	
quarantine.	But	finally,	population	testing	should	
be	considered.	Healthy,	immunocompetent	per‑
sons	may	return	to	normal	activities	and	work,	
because	they	have	already	been	infected	and,	pos‑
sibly,	they	are	resistant	to	reinfection	and	epide‑
miologically	safe	(they	do	not	transmit	infection);	
2)	to	verify	epidemiological	monitoring:	tracking	
of	patients’	contacts,	identification	of	virus	“res‑
ervoirs,”	the spread	of	infection	in	the observed	
population,	and	identification	of	asymptomat‑
ic	infections	in	particular;	3)	to	support	epide‑
miological	monitoring	of	patients	in	quarantine	
or	isolation	in	the absence	of	molecular	tests	or	
even	as	a cheaper	alternative	for	a molecular	test.	
We	suggest	testing	in	7	‑day	intervals	(on	day	7,	
14,	and	21).	Such	a procedure	should	be	efficient	
for	identifying	infected	patients,	even	those	as‑
ymptomatic,	and	follow	‑up	time	is	long	enough	
to	confirm	healthy	status	in	those	with	negative	
test	results.	Also,	new	technologies	could	be	in‑
volved.	For	example,	the patient	can	take	a pho‑
to	of	the cassette	after	performing	the test	and	
share	it	with	the physician,	who	will	profession‑
ally	interpret	the result	remotely.
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